Memic Innovative Surgery (Memic), a medical device company dedicated to transforming robot-assisted surgery with its proprietary technology, has closed a $96 million Series D financing round, the company announced Monday.
Follow Israel Hayom on Facebook and Twitter
The financing round was led by Peregrine Ventures and Ceros with participation from Ourcrowd and Accelmed. Funding will support commercialization of the Hominis robotic-assisted surgical platform in the US and potentially in other countries.
Memic co-founder and CEO Dvir Cohen said, "The Hominis system represents a significant advancement in the growing multi-billion-dollar robotic surgery market. This financing positions us to accelerate our commercialization efforts and bring Hominis to both surgeons and patients in the months ahead."
In February 2021, the Hominis system received De Novo marketing authorization from FDA for use in single site, natural orifice laparoscopic-assisted transvaginal benign surgical procedures, including benign hysterectomy.
The biomimetic instruments are designed to replicate the motions and capabilities of a surgeon's arms, with shoulder, elbow and wrist joints. Multiple instruments can be introduced to the body through a single portal.
"Given the broad potential of Hominis combined with a strong management team, we are proud to support Memic and execution of its bold vision," said Eyal Lifschitz, managing general partner of Peregrine Ventures.
"We are grateful for the opportunity to work with management on this exciting milestone for both Memic and the field of robotic surgery," said Mark Goldwasser, CEO of Ceros.
